庞永慧,苏敬华,武 珊

精神分裂症是一种慢性、复发率高、肇事肇祸风险高的精神病性障碍。我国有90%以上的精神分裂症患者生活在社区，但口服药物依从性差导致病情反复发作、社会功能受损。帕利哌酮是第二代抗精神病药物，其长效注射制剂—棕榈酸帕利哌酮通过提高治疗依从性、保持稳定的血药浓度，从而改善患者的整体预后。本文探讨帕利哌酮长效注射针剂在社区精神分裂症患者治疗中的益处，包括用药依从性、有效性、安全性和耐受性及选择意愿，旨在为精神分裂症患者社区管理及长效针剂实践探索提供一定的证据参考。虽然我国社区精神分裂症患者长效针的使用比例偏低，但相信国内会有更多应用研究以指导长效针剂在我国社区精神分裂症患者中的社区康复方案，也相信未来会有更多的患者从中受益。

精神分裂症；长效制剂；棕榈酸帕利哌酮；社区获益

[1] Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia:Findings from the global burden of disease study 2016[J].Schizophr Bull,2018,44(6):1195-1203. [2] 中华医学会精神医学分会精神分裂症协作组,中华医学会全科医学分会.社区应用抗精神病药长效针剂治疗精神分裂症专家共识[J].中国全科医学,2022,25(29):3587-3602. [3] 李佳博,欧阳江峰,杨丁,等.长效针剂在三省部分社区精神分裂症患者中的应用现状及存在问题[J].山东大学学报(医学版),2022,60(06):107-113+121. [4] Yalçin N, Ak S, Gürel ŞC, et al. Compliance in schizophrenia spectrum disorders: the role of clinical pharmacist[J]. Int Clin Psychopharmacol, 2019,34(6):298-304. [5] Bain EE, Shafner L, Walling DP, et al. Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia[J]. JMIR Mhealth Uhealth, 2017, 5(2):e18. [6] Sun Y, Tong J, Feng Y, et al. Attitude and influencing factors of patients with schizophrenia toward long-acting injections: A community-based cross-sectional investigation in China[J]. Front Public Health, 2022, 10:951544. [7] EL KHOURYA C, PILON D, MORRISON L, et al. The prospective economic impact of once monthly pali peridone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia[J]. Curr MedRes Opin, 2019, 35(3):395-405. [8] Young-Xu Y, Duh MS, Muser E, et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on health care re source use and costs in veterans w ith schizophrenia[J]. J Clin Psychiatry,2016,77(10):e1332-e1341. [9] Cassidy C, Miles W. New Zealand community mental healthcare provider experience in schizophrenia management with 3-monthly paliperidone palmitate[J]. Australas Psychiatry, 2021, 29(3): 299-304. [10] 刘岩.精神分裂症患者抗精神病药物治疗依从性研究进展[J].中国处方药,2023,21(08):187-189. [11] 陈龙涛,朱建忠,刘岱岳,等.棕榈酸帕利哌酮注射液治疗首发精神分裂症的疗效分析[J].青岛医药卫生,2022,54(03):196-198. [12] Gattaz W F,Saracco-Alvarez R,Daltio C S,et al.Treatment of patients with recently exacerbated schizophrenia with paliperidone palmitate:A pilot study of efficacy and tolerability[J]. Neuropsychiatric Disease and Treatment, 2020, 16: 2063-2072. [13] Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia[J]. J Clin Psychopharmacol, 2010, 30(3): 235-244. [14] Wang G, Huang H, Wang Y, et al. A randomized, prospective, active-controlled study comparing intramuscular long-acting paliperidone palmitate versus oral antipsychotics in patients with schizophrenia at risk of violent behavior[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2024, 129: 110897. [15] Ohnishi T, Kobayashi H, Yamaoka T, et al. The Effects of Paliperidone Palmitate 1 Month on the Employment Status and Social Functioning of Patients with Schizophrenia. Innov Clin Neurosci, 2020, 17(1-3): 36-44. [16] Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry, 2013, 12(3):216-226. [17] 张影,黄海锋,张传福,等.棕榈酸帕利哌酮长效针剂对社区精神分裂症患者临床症状与社会功能的影响[J].中华行为医学与脑科学杂志,2023,32(5):413-419.[18] Muser E,Kozma C M,Benson C J,et al.Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement[J]. Journal of Medical Economics, 2015, 18(8): 637-645. [19] 罗星.棕榈酸帕利哌酮长效针剂治疗精神分裂症的疗效及卫生经济学的研究[D].昆明医科大学,2023. [20] Gopal S, Xu H, Bossie C, et al. Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases[J]. International Journal of Clinical Practice, 2014, 68(12): 1514–1522. [21] Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison[J]. International clinical psychopharmacology, 2014, 29 (1): 45-55. [22] 王玉成,王云锋,杨红英,等.棕榈酸帕利哌酮长效针剂治疗精神分裂症效果观察[J].中国乡村医药,2021,28(18):14-16. [23] Savitz AJ, Xu H, Gopal S, et al. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study, Int J Neuropsychopharmacol. 2016, 19(7): pyw018. [24] 王继红,张文静,许立红.帕利哌酮对首次发作精神分裂症患者精神病症状及生活质量的影响[J].医药导报,2018,37(7):852-855. [25] Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study[J]. Neuropsychiatr Dis Treat, 2017, 13: 2193-2207. [26] 姜璎慈,田吉,张芬,等.精神分裂症患者使用抗精神病长效治疗药物意愿调查分析[J].同济大学学报(医学版),2022,43(01):120-124. [27] 黄庆之,陆维,马瑀涵,等.北京市社区严重精神障碍患者长效针剂选择意愿研究[J].精神医学杂志,2022, 35(05): 500-504. [28] 张鸿燕,黄继忠,司天梅,等.棕榈酸帕利哌酮临床使用指导意见[J].中国新药杂志,2014,12:1410-1417.

点击下载PDF